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Stem Cell Research (2008) 1, 183–194Isolation of major pancreatic cell types and long-term
culture-initiating cells using novel human
surface markers
Craig Dorrell ⁎, Stephanie L. Abraham, Kelsea M. Lanxon-Cookson,
Pamela S. Canaday, Philip R. Streeter, Markus GrompeOregon Health & Science University and the Oregon Stem Cell Center, 3181 SW Sam Jackson Park Road,
Portland, OR 97239, USAReceived 28 February 2008; received in revised form 15 April 2008; accepted 23 April 2008Abstract We have developed a novel panel of cell-surface markers for the isolation and study of all major cell types of
the human pancreas. Hybridomas were selected after subtractive immunization of Balb/C mice with intact or dissociated
human islets and assessed for cell-type specificity and cell-surface reactivity by immunohistochemistry and flow cytometry.
Antibodies were identified by specific binding of surface antigens on islet (panendocrine or α-specific) and nonislet pancreatic
cell subsets (exocrine and duct). These antibodies were used individually or in combination to isolate populations of α,
β, exocrine, or duct cells from primary human pancreas by FACS and to characterize the detailed cell composition of
human islet preparations. They were also employed to show that human islet expansion cultures originated from nonendocrine
cells and that insulin expression levels could be increased to up to 1% of normal islet cells by subpopulation sorting and
overexpression of the transcription factors Pdx-1 and ngn3, an improvement over previous results with this culture system.
These methods permit the analysis and isolation of functionally distinct pancreatic cell populations with potential for
cell therapy.
© 2008 Published by Elsevier B.V.Introduction
Although the transplantation of cadaveric human islets has
in some cases delivered long-term therapeutic benefit for
diabetes patients, the supply of transplantable material is
insufficient (Marzorati et al., 2007). Alternative sources ofAbbreviations: EMET, epithelial to mesenchymal to epithelial
transition; ICA, islet-like cell aggregate; DTZ, dithizone.
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doi:10.1016/j.scr.2008.04.001insulin-expressing cells have been studied, including
embryonic stem cells (Jiang et al., 2007), adult pancreatic
progenitors (Abraham et al., 2004; Bonner-Weir et al.,
2004), cultured islets (Gershengorn et al., 2004; Ouziel-
Yahalom et al., 2006) and other pancreatic tissues (See-
berger et al., 2006; Todorov et al., 2006), bone marrow cells
(Hess et al., 2003), liver cells (Ferber et al., 2000), and
certain cell lines (Narushima et al., 2005). However, the
identification, isolation, and manipulation of cells suitable
for transplantation are limited by the absence of tools for
the purification of normal islet cells or potential
substitutes.
Table 1 Novel monoclonal antibodies recognizing surface
antigens on distinct subsets of human pancreatic cells
Antibody Hybridoma
clone
Classification Isotype % of cells
positive
HPi1 HIC0-4F9 Pani-slet Mouse IgG1 55±7
HPi2 HIC1-2B4 Pani-slet Mouse IgG1 62±5
HPi3 HIC1-7H10 Pani-slet Mouse IgG1 51±11
HPα1 DHIC2-2C12 α Mouse IgM 12±3
HPα2 DHIC2-2B4 α Mouse IgG1 24±8
HPx1 HIC0-3B3 Exocrine Mouse IgG1 20±8
HPx2 HIC1-1C10 Exocrine Mouse IgM 14±5
HPd1 DHIC2-4A10 Duct Mouse IgG1 11±7
HPd2 DHIC3-5H10 Duct Mouse IgM 14±6
Antibody names are suffixed indicating lineage specificity: i, pani-
slet; α, α cell; x, exocrine; d, duct. The frequencies of binding to
cells obtained by enzymatic dispersal of human islet preparations
are reported as an average of three samples with declared purities
of 80–90% defined by DTZ staining (with contaminating exocrine or
duct cells as the remainder). Between 20,000 and 100,000 events
were collected per assay.
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tions selectively, and nearly all of these are nuclear or
cytoplasmic antigens and therefore inaccessible without
fixation (Maffei et al., 2004; Portela-Gomes et al., 2004).
The fluorescent zinc-chelating dye Newport green is differ-
entially retained by β cells (Lukowiak et al., 2001), but does
not clearly separate them from other pancreatic cells. Other
markers have quantitatively different rather than highly
specific expression patterns. Somatostatin receptor 2, for
example, is expressed on α cells but is also found at lower
levels on β and δ cells (Kumar et al., 1999). One success is
CA19-9, an antibody employed to isolate duct epithelial cells
from cultured human pancreas (Gmyr et al., 2004).
Several ex vivo culture strategies have been used to
generate human insulin-expressing cells. Of particular
interest is the report that human islet cells can be induced
to perform an “epithelial to mesenchymal to epithelial
transition” (EMET) in an appealingly straightforward long-
term culture (Gershengorn et al., 2004). Gershengorn et al.
showed that when cultured in serum-containing medium,
human islets initiate cultures of mesenchymal cells without
expression of epithelial/endocrine markers such as insulin.
Withdrawal of serum leads to downregulation of mesench-
ymal markers and the appearance of insulin expression,
albeit at a much lower level than in primary islets. Other
researchers have indicated that human ductal epithelia—in
addition to or instead of islet-derived endocrine cells—was
responsible for the establishment of cell cultures that
can give rise to insulin-expressing cells (Bonner-Weir
et al., 2000; Hao et al., 2006; Yatoh et al., 2007). Recent
experiments using mouse islets have suggested that murine
β cells do not undergo EMET (Atouf et al., 2007; Chase
et al., 2007; Morton et al., 2007; Weinberg et al., 2007).
However, without the ability to isolate different human
pancreatic cell types and test their capacities for culture
initiation, the nature of the human culture-initiating cell is
unclear.
Here, we report the development of monoclonal anti-
bodies that specifically recognize the surface of panendo-
crine, α, exocrine, and duct cells from human pancreas and
permit viable isolation of these populations. When human
islet samples were assessed for purity by flow cytometry, the
relative expression of endocrine-, exocrine-, and duct-
specific antigens was found to be predictive of insulin
mRNA content. Isolated human pancreatic cell populations
were tested for their capacity to initiate long-term expan-
sion cultures and produce insulin; nonendocrine cells were
best able to meet these criteria. Cultured cells expressing
the highest level of an endocrine-associated surface maker
initiated subcultures with superior insulin mRNA expression,
and the level was increased by Pdx-1 and ngn3 over-
expression. Future applications of these antibodies should
permit a greater understanding of pancreatic biology andFigure 1 Selective human pancreatic lineage labeling with mon
colabeled with supernatants from two hybridoma cell lines with ant
subset of HPi2+ islet cells (red). No overlap is observed between HPi2
bound by HPx2 (green; G–I). Distinct labeling is also observed in the
and HPx1 (red; M–O). Islet marker HPi1 (red) does not recognize e
pani-slet specificity in comparison with α marker HPα1 (green; S–
antibodies were FITC-conjugated anti-mouse IgM and Cy3-conjugatefacilitate the production of transplantable insulin-expressing
cells.
Results
The generation of monoclonal antibodies
recognizing the cell surface of human pancreatic
cell subsets
Three different immunization strategies were employed to
generatemouse anti-humanmonoclonal antibodies. The HIC0
and HIC1 series used intact islet immunization to minimize
manipulation of target cell antigens and, given that intact
islets have long-term stability, potentially to enhance
immunogenicity. The two protocols differed in that the latter
employed a specificity-enhancing subtractive immunization
step as described by Williams et al. (1992). The frequency of
clones with islet- or islet cell subset-specific labeling in the
HIC1 fusion was 28/768 (3.6%), compared with 12/768 (1.5%)
in HIC0. DHIC2/3, the third protocol, did not employ sub-
traction but used trypsin-dissociated islet cells rather than
intact islets for immunization to promote representation of
minor islet cell populations. Islet- or islet cell subset-specific
labeling in DHIC2/3 clones was observed at a frequency of
16/576 (2.7%).
Hybridoma supernatants were first screened for selective
activity against acetone-fixed human pancreatic tissue
sections, but only those that also bound the surface of viable
trypsin-dissociated single islet cells as demonstrated by flow-oclonal antibodies. Adult human pancreatic cryosections were
i-human pancreatic subset activity. (A–C) HPα1 (green) binds a
(red) and duct cells bound by HPd2 (green; D–F) or exocrine cells
comparison of HPx2 (green) and HPd1 (red; J–L) or HPd2 (green)
xocrine cells bound by HPx2 (green; P–R) and HPi3 (red) shows
U). All sections were labeled with Hoechst 33342; secondary
d anti-mouse IgG1–3.
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186 C. Dorrell et al.cytometric analysis were analyzed further. Approximately
14% of antibodies that labeled fixed pancreatic sections
were also detectable by flow cytometry; HIC0, HIC1, and
DHIC2/3 clones were very similar in this respect. Table 1
lists hybridomas that met these criteria and reproducibly
recognized cell subsets of interest in high-quality (≥80%
declared purity) human islet preparations (n=4). Represen-
tative examples of immunohistochemical labeling of human
pancreas are shown in Fig. 1. The choice of acetone fixa-
tion for screening was validated by the fact that para-
formaldehyde prevented labeling by all antibodies other than
HPi1 and HPα2. The proportions of cells recognized by anti-
bodies defined as pani-slet (HPi1–3), α-specific (HPα1, 2),
exocrine-specific (HPx1, 2), or duct-specific (HPd1, 2) cor-
responded to the expected frequencies of such cells in islet
preparations, but the frequency of labeling with islet-specific
(panendocrine or α-specific) antibodies was lower than thatFigure 2 Combination labeling with immunohistochemical marke
(red; B, C), whereas HPα2 (D) does not label insulin-expressing cells (E
acinar cells (green; G, I) albeit with distinct subcellular localization
recognized by HPd1 (red; K). The sections depicted in A–F were pa
required to preserve antigenicity.predicted by islet dithizone (DTZ) staining. This probably
reflects an overestimation of islet purity by dithizone staining
as previously described (Street et al., 2004) and discussed
below.
Fig. 2 depicts sections simultaneously labeled with novel
surface antibodies and commercial antibodies recognizing
insulin or amylase. As shown in Figs. 2A–C the pani-sletmarker
HPi1 labeled all endocrine cells, including but not limited
to, insulin-expressing β cells. The α-cell marker HPα2
recognized an islet cell subpopulation distinct from β cells
(Figs. 2D–F). The populations labeled by the exocrine marker
HPx1 (Figs. 2G–I) or duct marker HPd1 (Figs. 2J–L) overlapped
with amylase or cytokeratin 19 (CK19) expression, respec-
tively. The HPd antibodies label large ducts that are invariably
CK19+, but smaller intercalating ducts are HPd1/2−. The
specificities of these antibodies, aloneor in combination,were
further evaluated by molecular analysis of cell populationsrs. HPi1 binding (green; A) exhibits partial overlap with insulin
, F). (H–I) Exocrine marker HPx1 (red; H) labels amylase-positive
. A subset of duct cells bound by cytokeratin 19 (green; J, L) is
raformaldehyde-fixed, whereas G–L were fixed with acetone as
Table 2 Gene expression analysis of antibody-labeled human pancreatic cell subsets
Expression relative to unsorted dispersed islet cells Linear ratios
Cell population Classification Insulin Glucagon Somatostatin PP Ghrelin CK19 Trypsin Insulin: glucagon Insulin: CK19 Insulin: trypsin
Unsorted dispersed islet cells 1 1 1 1 1 1 1 18.4 1097 4.0
Hpi1+ Islet enriched 9.19 512 37 7.46 1.07 0.308 0.005 0.33 32,768 7643
Hpi1− Islet depleted 0.001 0.063 0.077 0.308 1.74 0.177 3.48 0.22 4.6 0.001
Hpi2+ Islet enriched 49 724 111 4.59 0.536 1.52 0.003 1 35,120 75,281
Hpi2− Islet depleted 0.041 0.616 0.933 0.125 2.64 45 4.92 1.23 1.00 0.03
Hpi3+ Islet enriched 23 512 91 84 1.23 3.48 0.004 0.812 7132 21,619
Hpi3− Islet depleted 0.003 0.165 0.287 0.218 0.574 2.83 1.62 0.31 1.07 0.01
HPα1+ α enriched 1.52 147 6.1 39 0.041 0.250 0.002 0.19 6654 2521
HPα1− α depleted 34.3 8.0 10.6 64 1.52 0.660 0.871 79 57,052 158
HPα2+ α enriched 0.029 0.330 1.15 4.29 0.203 0.354 0.088 1.6 91 1.3
HPα2− α depleted 0.041 0.154 2.83 13.0 3.03 0.871 0.871 4.9 51.98 0.19
HPx1+ Exocrine enriched 0.0005 0.218 2.14 0.268 0.933 0.117 13 0.04 4.3 0.0001
HPx1− Exocrine depleted 1.23 239 194 4.0 18.4 0.250 0.021 0.09 5405 239
HPx2+ Exocrine enriched 0.002 0.072 1.0 0.154 1.74 0.435 14 0.41 4.0 0.0005
HPx2− Exocrine depleted 0.758 64 3.0 3.73 5.28 0.109 0.007 0.22 7643 446
HPd1+ Duct enriched 0.0001 0.004 1.4 0.003 0.117 39 0.007 0.29 0.002 0.04
HPd1- Duct depleted 0.308 8.0 158 0.871 1.41 1.87 0.707 0.71 181 1.74
HPd2+ Duct enriched 0.0001 0.003 2.1 0.013 0.095 49 0.004 0.87 0.003 0.13
HPd2− Duct depleted 0.117 8.0 64.0 3.48 0.758 2.30 0.933 0.27 55.7 0.50
HPx2+/HPd1− Exocrine enriched 0.002 0.812 0.536 0.109 0.406 0.044 21 0.04 39 0.0003
HPx2−/HPd1+ Duct enriched 0.0003 0.001 59.7 137 5.66 28 0.007 4.00 0.01 0.18
Hpi2+/HPα1−/ HPx2− β enriched 5.7 0.027 3566 137 0.077 0.025 0.004 3822 244,589 5043
Hpi2+/HPα1+/ HPx2− α enriched 0.027 17.1 18 26 3.48 0.015 0.001 0.03 2048 208
QPCR ΔCt values were obtained as the cycle threshold for the gene of interest minus the average of the Ct values observed for the housekeeping genes lamin and 18S RNA. The ratio between this
value and that for unsorted dispersed islet cells for each gene is reported. The linear ratios of insulin mRNA to the other three lineage-selective genes indicate the degree of enrichment for the
associated cell type within each sorted population. Each sort was performed from two different high-purity (85–90%) islet preparations, and cDNA for each sorted population was amplified
twice; thus, each ratio reported is derived from the average of four QPCR evaluations.
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Figure 3 Flow-cytometric analysis of subsets of viable human pancreatic cells. (A–C) The nonspecific labeling of the secondary antibodies employed to detect intracellular and
extracellular labels. Marking of pancreatic cells with antibodies recognizing cell-surface antigens specific to islets (D, E), exocrine cells (F, G), or ducts (H, I) was compared with
intracellular labeling of insulin (B, D, F, H) or amylase (C, E, G, I). Human C-peptide levels were evaluated in cells labeled with anti-islet antibody HPi2 (J) or the combination of non-β
antibodies HPx2 and HPα1 (K). Combined labeling with islet, α, and exocrine antibodies permitted efficient simultaneous separation of populations enriched for α and β cells from the
remaining pancreatic cell types (L), as indicated by the their insulin levels (M).
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Figure 4 Antibody binding frequencies reflect human islet
preparation purity. Three islet samples were assessed for purity
on the basis of DTZ staining, insulin mRNA levels, and the relative
frequencies of cell labeling with lineage-specific cell labeling as
measured by flow cytometry. Declared purity (by DTZ) and anti-
body binding frequencies are shown on the left axis, and the
absolute ratio of insulin:lamin mRNA for each sample as deter-
mined by QPCR is indicated on the right.
189Human pancreatic cell surface markerssorted from the dispersed islet populations listed in Table 2.
Populations selected for the expression of the pani-slet surface
markers HPi1–3 had high levels of pancreatic islet-associated
mRNA (insulin, glucagon) and reduced levels of duct (CK19) or
exocrine (trypsin) mRNA. Labeling with a single α-specific
antibody (HPα1) produced strong α-cell enrichment as
indicated by a N100-fold higher glucagon mRNA content in
HPα1+ cells relative to unsorted islet cells. Although a β-cell-
specific antibodywas not generated in these studies, dramatic
β-cell enrichmentwas achievedwith a combination of positive
selection for endocrine cells (HPi2+) and depletion of cells
recognized by α-cell (HPα1) or exocrine (HPx2) markers (Table
2 and Fig. 3). As indicated, HPi2+/HPα1−/HPx2− cells had an
insulin:glucagon mRNA ratio more than 200× greater than that
of cells from high-quality (≥85% declared purity) islet
preparations. Combination labeling also yielded superior
enrichment of α cells: HPi2+/HPα1+/HPx2− cells had a
glucagon:insulin mRNA ratio more than 600× higher than that
found in unsorted islet preparations (Table 2).
The antibodies generated here were also successfully used
to identify and/or isolate endocrine cells from “low-quality”
islet preparations inadequate for clinical application. As
shown in Fig. 3, flow-cytometric detection of intracellular
insulin was restricted to antibody-defined endocrine popula-
tions (HPi2+, HPx1−, or HPd1−; Figs. 3D, F, H), whereas
amylase was found in the more abundant exocrine fractions
(HPi2−, HPx1+, HPd1−; Figs. 3E, G, I). The islet preparation
depicted (Figs. 3A–I) had a declared purity of 30%. However,
clear enrichment of β cells was achieved with islet samples of
even lower purity (Figs. 3J–M). Combined labeling with HPi2,
HPα1, and HPx2 revealed that C-peptide could be detected
only in cells positive for HPi2 (Fig. 3J) or negative for both
HPx2 and HPα1 (Fig. 3K). Neither the HPi2+HPα1+ (α cell) nor
the HPi2− (exocrine and duct) populations contained sig-
nificant insulin, but 91% of the cells in the β-cell-enriched
HPi2+/HPx2−/ HPα1− fraction were insulin positive (Figs. 3L
and M). Comparatively rare islet components such as δ and
PP cells probably comprise the insulin-negative subfractions
within this population.
Evaluation of human pancreatic islet preparations
by antibody labeling
The quality of human islet preparations is routinely assessed
by staining with DTZ, an optically active zinc-chelating dye
(Latif et al., 1988). A comparison of DTZ labeling results,
insulin mRNA levels, and antibody labeling frequencies for
three islet samples (with declared purities of 90, 80, and
35%) is shown in Fig. 4. Good overall agreement was ob-
served, but DTZ staining tended to overestimate islet purity.
This is particularly evident in lower quality (b40% declared
purity) samples, in which the frequency of recoverable cells
with an antibody-defined endocrine phenotype (HPi1+,
HPi2+, or HPx1−/HPd1−) was as low as half of the level
predicted by DTZ. Relative insulin mRNA levels correlated
well with HPi2 and HPi1 labeling and correlated inversely
with HPx1 or HPd1 labeling. Note that DTZ islet purity scores
were provided by the facility that isolated them; it is possible
that differential loss of islet cells may have occurred during
the delay (24–36 h) between shipment and evaluation in our
laboratory.Cell cultures derived from FACS-sorted islet
cell subsets
By sorting the cells recognized by the antibodies described
herein using FACS, we evaluated the potential of distinct
populations to initiate cultures and proliferate in the serum-
containing cultures described by Gershengorn et al. (2004)
and to produce insulin upon serum withdrawal. Preliminary
experiments indicated that, whereas most islets from
clinically prepared samples adhered to tissue culture-treated
plasticware and produced a local outgrowth of cells, less than
0.5% of enzymatically dispersed cells from typical prepara-
tions became adherent and proliferated in culture. A
comparison of the growth of cells positively or negatively
identified by endocrine-labeling antibodies HPi1 or HPi2
showed that endocrine cells had a poor capacity for culture
initiation, whereas cells lacking islet markers grew well
(Table 3). Conversely, a comparatively high percentage of
HPd1+ cells grew in culture. Although most populations had
some ability to proliferate in culture, some cell types
(particularly HPα1+ cells) ceased proliferation much earlier
than others. Populations that expanded for at least 1month in
culture were then tested for their ability to form islet-like
cell aggregates (ICAs) upon serum withdrawal as previously
reported; as shown in Table 3, this capacity was strongest in
cultures initiated by endocrine-depleted (HPi2− or HPi1−) or
duct-enriched (HPd1+) fractions.
Cultured cells were assayed tomeasure the extent towhich
an islet cell-like marker profile was maintained during pro-
liferation in serum-containingmedium. The proportion of cells
labeled by HPi1 declined and became undetectable by passage
3, consistent with the absence of endocrine characteristics
such as insulin expression (described below). Although the
percentage of HPi2+ and HPi3+ cells also declined over the first
Table 3 Culture initiation and maintenance by antibody-defined pancreatic cell subsets
Proliferative expansion
Population Classification Culture-initiating cell frequency Day 0–30 Day 0–60 Day 30–60 ICA formation
Unsorted 1/6000 7500 7,132,500 951 ++
HPi1+ Islet 1/6500 12,500 212,500 17 −
HPi1− Nonislet 1/900 41,363 39,294,850 950 ++
HPi2+ Islet 1/12,000 45,000⁎ NA 0 −
HPi2− Nonislet 1/450 3900 8,541,000 2190 ++
HPα1+ α 1/1600 6000⁎ NA 0 NA
HPα1− Non-α 1/900 32,500 7,995,000 246 +
HPx1+ Exocrine 1/770 4700 646,250 138 +
HPx1− Nonexocrine 1/3333 12,666 10,006,140 790 +
HPd1+ Duct 1/450 16,000 16,320,000 1020 +++
HPd1− Nonduct 1/6000 21,225 955,125 45 +
Culture-initiating cell frequency was determined 10 days after plating by counting the number of distinct clusters of healthy cells per plate
relative to the input cell number. Proliferative expansion values indicate total cell counts measured after 30 and 60 days of continued
growth (with culture passage and medium feeding as required, divided by the total number of clones scored). Asterisks indicate
cultures that had ceased to proliferate by the 30-day time point. ICA formation capacity was judged 5 days after transfer into serum-free
medium and is a measure of the fraction of cells that contribute to ICA formation and extent to which spheroids were formed (as opposed
to groups of adherent cells or partially detached cell aggregates).
190 C. Dorrell et al.two passages, it subsequently increased such thatN95% of cells
were labeled by passage 4 and later time points. This change in
antigenicity was likely a result of adaptation to culture;
several human cell lines such as Panc1 (adenocarcinoma) and
Huh7 (hepatoma) are 100% positive for HPi2 and HPi3 but
negative for HPi1 (data not shown). Thus, despite their equiv-
alence on primary cells, marking by HPi1 was a more useful
indicator of insulin expression than HPi2 or HPi3 for cultured
cells.
The derivation of insulin-expressing cells in culture
Previous reports using this culture assay achieved mRNA
levels approximately 106-fold lower than primary β cells. We
therefore evaluated whether pancreatic surface markers
could be used to obtain cells with higher insulin expression.
The gene expression status of islet-derived cell cultures was
examined in cells after expansion (between 105 and 4×106-
fold) in serum-containing culture with or without serum
withdrawal-stimulated ICA formation. Antibody-defined sub-
populations of cells from ICAs were also examined, as were
ICA cells that had been treated with adenovirus to deliver
Pdx-1 and/or ngn3 (Table 4). Cell line 1 is an example derived
from cultured intact islets. As indicated, a substantial
elevation of insulin mRNA levels and a modest decrease in
vimentin mRNA were observed when cells from the serum-
containing and ICA environments were compared. As shown in
Table 4, a line initiated by HPi1− cells (endocrine-depleted,
N99% pure) gave similar results, indicating that β cells were
not required to initiate cultures capable of eventual insulin
expression. The cells within ICAs were not homogeneous with
respect to morphology or surface marker expression, so we
investigated whether insulin expression was also heteroge-
neous. When cells derived from an intact islet-derived line
(cell line 3) were used to form ICAs and the cells within these
structures were dispersed, labeled with HPi2 or HPi3, and
flow sorted, all of the detectable insulin mRNA (at levels
approximately 2000-fold lower than in intact islets) wasfound in the HPi2− and HPi3− fractions. This low level of
insulin expression may reflect incomplete reprogramming to
a β cell transcriptional state. To produce a more β-cell-like
transcriptional environment, adenoviral delivery of the
pancreatic lineage transcription factors Pdx-1 and ngn3 was
employed. As listed in Table 4, Pdx-1 expression clearly
enhanced per-cell insulin mRNA expression relative to
uninfected or AdV-ngn3-transduced cells. Furthermore, co-
infection with two vectors (m.o.i. 20:1 for AdV-Pdx-1 and 2:1
for AdV-ngn3) yielded cells with insulin mRNA 1.1% of that of
primary islet cells (Table 2) in cell line 2 or 0.06% of primary
islet cells in cell line 3. Nevertheless, vimentin was expressed
at levels only a few fold lower than in the serum-containing
culture. This suggests that insulin expression in these cultures
is not associated directly with the substantial loss of mesen-
chymal characteristics.
Discussion
Reagents permitting the viable fractionation of cell lineages in
solid organs are scarce, particularly for endodermal tissues. As
a result, characterization of the various cell types present in
these tissues is limited compared to the hematopoietic system,
in which hundreds of useful markers can be assessed by FACS
or immunomagnetic separation (Mason et al., 2002). In the
mouse, this deficiency has been partially compensated for by
the generation of transgenic mice in which specific cell
lineages have fluorescent tags (Hara et al., 2003). For human
cells, however, solid tissue equivalents to the hematopoietic
“CD antigens” are needed. To this end, we have generated a
panel of cell-surface-binding monoclonal antibodies, which,
for the first time, permit the viable isolation of most major
human pancreatic cell types, including the two major endo-
crine cell types (α and β), exocrine cells, and ducts. Immuno-
histochemistry and mRNA analysis of isolated populations
demonstrated a high level of specificity. Combinations of these
antibodies were used for quantitative assessment of islet
preparation purity, including the proportions of endocrine
Table 4 Gene expression analysis of islet-derived cultures
ΔCt relative to lamin and 18S RNA
Cell population Treatment/
subfraction
Insulin Glucagon PC1/3 CK19 Vimentin Rat Pdx-1 Human
Ngn3
Unsorted dispersed islet cells (None) 1.6×102 8.6×100 1.2×10−1 1.4×10−1 − − −
Cell line 1 Serum-containing 2.2×10−5 6.3×10−7 2.9×10−6 Nd 3.5×10−1 − −
ICA 5.2×10−3 7.9×10−4 2.8×10−5 Nd 1.2×10−1 − −
HPi1− line (islet depleted) Serum-containing Nd 1.1×10−5 8.9×10−7 1.3×10−6 6.6×10−1 − −
ICA 1.4×10−3 1.0×10−3 4.6×10−5 Nd 3.3×10−2 − −
Cell line 3 ICA, Hpi2dim/+ Nd 2.4×10−4 nd 1.5×10−3 4.1×10−1 − −
ICA, Hpi2− 3.8×10−2 Nd 1.0×10−5 1.5×10−2 5.7×100 − −
ICA, Hpi3+ Nd Nd 1.4×10−6 7.9×10−4 6.2×10−1 − −
ICA, Hpi3− 5.1×10−2 2.2×10−2 4.6×10−5 4.2×10−3 3.7×100 − −
Cell line 2 Serum-containing 3.8×10−6 2.1×10−4 nd Nd 9.3×10−1 Nd 2.5×10−5
ICA 1.9×10−4 1.1×10−2 1.8×10−6 Nd 2.5×10−1 Nd Nd
ICA + AdV-pdx-1 1.4×100 2.3×10−1 7.9×10−4 Nd 1.5×10−1 2.7×10−1 Nd
ICA + AdV-ngn3 4.4×10−7 4.5×10−3 1.3×10−4 Nd 2.4×10−2 Nd 1.3×10−2
ICA + AdV-pdx-1 +
AdV-ngn3
2.3×100 3.5×100 1.7×10−4 Nd 6.2×10−1 3.8×10−1 2.3×10−1
Cell line 3 Serum-containing Nd 3.1×10−5 1.8×10−6 8.9×10−7 3.0×100 7.2×10−7 Nd
ICA 4.0×10−4 1.1×10−3 2.7×10−6 Nd 1.3×10−1 Nd 1.3×10−6
ICA + AdV-pdx-1 5.4×10−2 2.1×10−3 9.4×10−6 Nd 4.7×10−2 2.7×10−1 Nd
ICA + AdV-ngn3 2.8×10−5 4.6×10−4 4.6×10−5 Nd 3.6×10−2 2.4×10−7 4.7×10−2
ICA + AdV-pdx-1 +
AdV-ngn3
1.3×10−1 3.8×10−2 5.7×10−5 Nd 2.2×10−1 5.4×10−1 1.4×10−1
Three lines derived from intact islets (cell lines 1–3) and the HPi1− line established from an islet preparation sorted to remove endocrine
cells were assayed after at least eight passages (N40 days of culture) without loss of proliferative capacity. In experiments in which
adenoviral introduction of pancreatic regulatory factors was used, the expression of these genes (rat Pdx-1 and human ngn3) was
also assessed. Each experimental condition was repeated by thawing cryopreserved aliquots to compare identical passage numbers.
Values are expressed as linearized ΔCt relative to the average Ct of human lamin and 18S RNA. Each is the average of three
independent cDNA amplifications. nd, not detected (no amplification detected after 45 cycles).
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contaminating cells present; such assays may prove useful for
the identification of samples suitable for transplantation.
Identification of the antigen associated with each antibody is
in progress; because the cell surface is the site of important
functional and regulatory molecules, such as transporters and
signal receptors, this information should provide insight into
the biology of these cell populations.
Human islet cultures with the capacity for insulin expres-
sion were efficiently established after antibody-mediated
removal of endocrine cells, indicating that β cells were not
the initiating population. Accordingly, it should be possible
to derive insulin-expressing cells from the pancreata of
patients with type 1 diabetes despite their β-cell deficiency.
Positive selection of HPd1+ duct cells produced an improve-
ment in culture initiation but it is premature to conclude that
these cultures are always derived from pancreatic ducts.
Although the duct markers reported here strongly label
immunohistochemically identifiable ducts, colabeling with
CK19 suggests that smaller ducts are not recognized and
were not present in the sorted populations. Furthermore,
since the most enriched fraction of culture-initiating cells
described here produced only 1 cell cluster/450 plated cells,
a potential contribution by contaminating cells cannot be
excluded.
The insulin-producing cells generated by human islet
expansion culture are clearly distinct from true β cells,despite the islet-like spheroid morphology of the ICAs that
emerge after serum withdrawal. The continued expression of
high levels of vimentin and coexpression of glucagon, even in
the cells with the highest levels of insulin expression, are
inconsistent with the transcriptional profile of a primary
β cell. Enforced expression of Pdx-1 and ngn3 resulted in
substantial upregulation of insulin mRNA, but the highest
observed level was ~1% of that found in normal islets.
Additional reprogramming steps may yield further increases
in insulin expression and reduce the expression of genes
inconsistent with primary β-cell identity.
Given the apparent nonendocrine origin of these human
pancreatic islet cultures and their modest capacity for
insulin expression despite virally mediated expression of
key pancreatic lineage factors, therapeutic utility seems
limited. Nonetheless, the antibodies generated in this study
and their associated surface antigens should prove useful for
the isolation of cells from progenitor-derived cell popula-
tions from the adult pancreas or from differentiation
cultures initiated by human ES or ES-like populations
intended to yield functional β cells. The generation of cells
with a β-like surface phenotype should be a useful measure
of the success of such culture systems and permit their
isolation from heterogeneous populations. Suitable trans-
plantable β cells, regardless of their origin, should have a
HPi+/HPα−/HPx−/HPd− surface phenotype similar to that of
freshly isolated β cells.
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Tissue sources and cell isolation
Human islet samples (20–95% pure) were generously provided
by the Islet Cell Resource Center network (http://www.ncrr.
nih.gov/clinical_research_resources/resource_directory/
islet_cell_resource_centers/). Islets were collected after
100–700min of cold ischemia and cultured in CRML for 6–48 h
prior to overnight shipment. Cell viability on arrival (assessed
by trypan blue staining) was 95–99%. For preparation of a
single-cell suspension, islets were washed with DPBS
(Hyclone, Logan, UT, USA) before incubation in 3 ml 0.05%
HyQ trypsin (Hyclone). Digestion was continued for 10 min at
37 °C with gentle dispersal by pipetting with a p1000 micro-
pipettor every 3 min. Undispersed material was removed by
passage through a 40-µm strainer (BD Falcon, Bedford, MA,
USA) and 1 ml fetal bovine serum (FBS) was slowly added to
wash cells through the strainer, inhibit trypsin activity, and
gradually increase the calcium concentration. Cells were
then washed and resuspended in serum-free CMRL for brief
storage prior to antibody labeling or mouse immunization.
For immunohistochemical screening, an intact human
donor pancreas was provided by Dr. Susan Orloff (OHSU). Six
hours after harvest, portions of the organ were embedded in
Tissue-Tek cryomatrix (Sakura, Tokyo, Japan) and stored at –
86 °C prior to cryosectioning.
Antibody production
Animal care and immunizations followed protocol A982 of
the institutional review committee at Oregon Health &
Science University. Balb/C mice were inoculated (2× or 3×)
intraperitoneally (IP) with 5000–10,000 intact (HIC0/1
immunizations) or dissociated (DHIC2/3 immunizations)
islets. For the HIC1 fusion, subtractive immunization
(Williams et al., 1992) was employed. Briefly, the mouse
was preimmunized with unwanted antigens including 1×106
human peripheral blood cells, FBS, and small amounts of
trypsin. Cyclophosphamide (Sigma–Aldrich; 200 mg/kg) was
then injected IP after 24 and 48 h to eliminate B lymphocytes
reacting against these antigens. Islet inoculations were
administered to the pretreated animal 19 days (dose 1) and
38 days (boost) after the initial treatment. Four days after
the final immunization, animals were sacrificed and their
spleens harvested. Splenocytes were fused with SP2/0 Ag14
myeloma cells (Kohler and Milstein, 1975) and selected by
growth in methylcellulose-containing HAT medium (Stem
Cell Technologies, Inc., Vancouver, BC, Canada). Approxi-
mately 600 isolated clones were transferred to liquid
medium in 96-well plates. Supernatant screening employed
immunohistochemistry on human pancreas sections and flow
cytometry on dispersed human pancreatic islet samples.
Immunohistochemistry
Cryosections (5 µm) of adult human pancreas were prepared
using a Reichert 2800 Frigocut (Reichert Scientific Instru-
ments) and fixed by 10 min exposure to acetone at −20 °C or
(less frequently) paraformaldehyde at 4 °C. After drying,
slides were stored at −86 °C for up to 1 month. Primarylabeling was performed with 100 µl of undiluted hybridoma
supernatant for 30 min and secondary labeling with a 1:200
dilution of Cy3-conjugated goat anti-mouse IgG (Chemicon,
Temecula, CA, USA) in 2% FBS (Hyclone) and 2% rat serum for
20 min. A Zeiss Axioskop 2 Plus (Carl Zeiss, Jena, Germany)
was used for evaluation and photography.
Flow cytometry and FACS
Dissociated cells from primary islets or cell cultures were
resuspended in 100 µl DPBS + 2% FBS, combined with an equal
volume of hybridoma supernatant and stored at 4 °C for
30 min. Cells were then washed with cold DPBS and resus-
pended in 100 µl DPBS + 2% FBS containing propidium iodide
and a 1:200 dilution of secondary antibody. Secondary anti-
bodies employed included anti-mouse IgG (H+L) conjugated
to APC or PE, PE-conjugated anti-mouse IgM (µ chain-
specific), and APC-conjugated anti-mouse IgG subclasses 1
+2a+3 (Jackson ImmunoResearch,West Grove, PA, USA). Dead
cells were stained with propidium iodide (10 µg/ml). For
combined intra- and extracellular labeling, cells were then
fixed for 20 min in 2% paraformaldehyde, washed in DPBS,
incubated with antibodies recognizing human amylase or
insulin (Santa Cruz) or human C-peptide (BCBC), followed by a
suitable secondary antibody (anti-rabbit FITC or anti-rat
FITC; Jackson ImmunoResearch). Postfixation washes and
incubations were performed in the presence of 0.5% saponin
(Sigma–Aldrich) and 2% FBS. Cells were analyzed using a
Becton–Dickinson FACSCalibur or sorted with a Cytopeia
inFluxV-GS, and where possible electronic gating was used to
exclude cell doublets (by FSC:pulse width ratio) from analysis
or collection.
RNA isolation and real-time PCR
Sorted cells were pelleted and flash frozen prior to RNA
isolation with Trizol (Invitrogen). First-strand cDNA synthesis
employed MMLV reverse transcriptase and random oligonucleo-
tide primers (Invitrogen). RNA levels were assessed by quan-
titative real-time PCRusing a Bio-Rad iCyclerwith a single-color
MyiQ detection system. All reactions were performed using 45
cycles of 15 s at 95 °C, 20 s at 68 °C, and 25 s at 72 °C. Reaction
mixtures included Platinum Taq DNA polymerase (Invitrogen),
2.5 mM MgCl2, 10 µM 5′ and 3′ primers, 10 mM dNTPs, and 0.5×
SYBR green. Primers included insulin (5′, CGCAGCCTTTGT-
GAACCAACAC; 3′, AAGCCTCGTTCCCCGCACACTA), glucagon (5′,
AGCTTCCCAGGCAGACCCACTC; 3′, ATGGCGCTTGTCCTCGTT-
CATC), somatostatin (5′, GCTGCTGTCTGAACCCAACCAGA; 3′,
TCAAGCCTCATTTCATCCTGCTCA), PP (5′, TCTCCCTGC-
TGCTCCTGTCCAC; 3′, CCATCTGCTCTGGTGTGGCATT), ghrelin
(5′, TTCAACGCCCCCTTTGATGTTG; 3′, GCCTCTTTGGCC-
TCTTCCCAGA), PC1/3 (5′, CCGGAGGGATGAGTTGGAGGAG;
3′, TGGTGATTGCTTTGGCGGTGAG), trypsin (5′, TGGT-
GGCTCCCTCATCAACGAA; 3′, GCTCTCCCAGTCTCACCTG-
GATGC), cytokeratin 19 (5′, AGGCCAGGTCAGTGTGGAGGTG;
3′, ATTGGCTTCGCATGTCACTCAGG), vimentin (5′, GTGTATGC-
CACGCGCTCCTCTG; 3′, GCCAGCGAGAAGTCCACCGAGT), Ngn3
(5′, ACTGAGCAAGCAGCGGGAGT; 3′, CGTCCAGTGCCGAGTT-
GAGGTT), rat Pdx-1 (5′, TTCCCGAATGGAACCGAGACTG; 3′,
CGCGTGAGCTTTGGTGGATTTC), lamin (5′, AGATGCGGGCAAG-
GATGCAG; 3′, CCTCCTCGCCCTCCAAGAGC), and 18S RNA (5′,
193Human pancreatic cell surface markersCAGCAGGCGCGCAAATTACC; 3′, GGCACCAGACTTGCCCTCCA).
Gene expression levels were reported as the difference
between baseline-corrected, curve-fitted cycle thresholds
for the gene of interest minus the average cycle thresholds of
two housekeeping genes (lamin and 18S RNA).
Islet-cell-derived cultures
Intact islets and dissociated cells were washed and seeded at
18 islets/cm2 and 100 cells/mm2, respectively, in CMRL1066
medium (Invitrogen) containing 10% FBS. Cells typically
adopted a fibroblast-like appearance and grew to high den-
sities, as described by Gershengorn et al. (2004). Cultures were
passaged by trypsinization and split 1:4 when near confluence;
this typically required 5–7 days. Medium changes were per-
formed every 3 days. Only cultures that continued to
proliferate for at least 30 days were regarded as lines. The
generation of spheroid ICAs was achieved by reseeding
trypsinized cells in serum-free CMRL at 300 cells/mm2. After
4–5 days of culture, ICAs were collected by replacing the
medium with Ca2+/Mg2+-free DPBS and gently pipetting to
release loosely attached clusters.
Culture-initiating cell frequencies were compared
between different flow-sorted populations by counting the
number of distinct clones of healthy cells per plate relative
to the input cell number, 10 days after seeding. Per-clone
proliferative capacities were measured by cell counts after
30 and 60 days of continued growth (with culture passage and
medium feeding as required), divided by the total number of
clones scored. ICA formation capacity was judged 5 days
after transfer to serum-free medium and is a measure of the
fraction of cells that contribute to spheroid formation and
extent to which spheroids are formed (as opposed to groups
of adherent cells or partially detached cell aggregates).
Adenovirus production and application
Adenoviral vectors expressing rat Pdx-1 (AdV-Pdx-1), human
ngn3 (AdV-ngn3), or EGFP (AdV-EGFP) were generously
provided by Michael German (University of California at San
Francisco). Large-scale virus production used cesium chlor-
ide gradient purification of infected 293 cells. Viral titer was
determined by flow-cytometric assessment of hexon protein
expression on 293 cells (using mouse anti-hexon (Clontech)
and APC-conjugated donkey anti-mouse IgG (Jackson Immu-
noResearch)) 24 h after infection with serial dilutions of
adenovirus.
Islet cell cultures were infected with AdV-Pdx-1 (m.o.i.
10:1) and/or AdV-ngn3 (m.o.i. 2:1) during replating in serum-
free medium. Free virus was removed by medium replace-
ment after 24 h. Transduction efficiency was N95% as
determined by flow-cytometric assessment of EGFP expres-
sion in cells transduced with AdV-EGFP at an m.o.i. of 2:1.
Statistical analysis
Statistical mean and standard deviation data were obtained
with Microsoft Excel. Curve fitting of QPCR cycle threshold
results was generated by MyIQ and IQ5 software (Bio-Rad).
Flow-cytometric population distribution data were provided
by FlowJo (Treestar, Ashland, OR, USA).Acknowledgments
We are grateful for Allan Kachelmeier’s assistance with cell
isolation. Thalida Arpawong, John Kaddis, Shaoping Deng, and
Martha Antler were invaluable for islet sample acquisition.
Lamin primers were provided by Qinghong Zhang and David
Keller. This work was supported by NIH/NIDDK Grant U01
DK072477 (Beta Cell Biology Consortium).
Appendix A. Supplementary data
Supplementary data associatedwith this article can be found,
in the online version, at doi:10.1016/j.scr.2008.04.001.
References
Abraham, E.J., Kodama, S., Lin, J.C., Ubeda, M., Faustman, D.L.,
Habener, J.F., 2004. Human pancreatic islet-derived progenitor
cell engraftment in immunocompetent mice. Am. J. Pathol. 164,
817—830.
Atouf, F., Park, C.H., Pechhold, K., Ta, M., Choi, Y., Lumelsky, N.L.,
2007. No evidence for mouse pancreatic beta-cell epithelial–
mesenchymal transition in vitro. Diabetes 56, 699—702.
Bonner-Weir, S., Taneja, M., Weir, G.C., Tatarkiewicz, K., Song, K.H.,
Sharma, A., O'Neil, J.J., 2000. In vitro cultivation of human islets
from expanded ductal tissue. Proc. Natl. Acad. Sci. U. S. A. 97,
7999—8004.
Bonner-Weir, S., Toschi, E., Inada, A., Reitz, P., Fonseca, S.Y., Aye, T.,
Sharma, A., 2004. The pancreatic ductal epithelium serves as a
potential pool of progenitor cells. Pediatr. Diabetes 5 (Suppl. 2),
16—22.
Chase, L.G., Ulloa-Montoya, F., Kidder, B.L., Verfaillie, C.M., 2007.
Islet-derived fibroblast-like cells are not derived via epithelial–
mesenchymal transition from Pdx-1 or insulin-positive cells.
Diabetes 56, 3—7.
Ferber, S., Halkin, A., Cohen, H., Ber, I., Einav, Y., Goldberg, I.,
Barshack, I., Seijffers, R., Kopolovic, J., Kaiser, N., Karasik, A.,
2000. Pancreatic and duodenal homeobox gene 1 induces expres-
sion of insulin genes in liver and ameliorates streptozotocin-
induced hyperglycemia. Nat. Med. 6, 568—572.
Gershengorn, M.C., Hardikar, A.A., Wei, C., Geras-Raaka, E.,
Marcus-Samuels, B., Raaka, B.M., 2004. Epithelial-to-mesench-
ymal transition generates proliferative human islet precursor
cells. Science 306, 2261—2264.
Gmyr, V., Belaich, S., Muharram, G., Lukowiak, B., Vandewalle, B.,
Pattou, F., Kerr-Conte, J., 2004. Rapid purification of human
ductal cells from human pancreatic fractions with surface
antibody CA19-9. Biochem. Biophys. Res. Commun. 320, 27−33.
Hao, E., Tyrberg, B., Itkin-Ansari, P., Lakey, J.R., Geron, I., Monosov,
E.Z., Barcova, M., Mercola, M., Levine, F., 2006. Beta-cell
differentiation from nonendocrine epithelial cells of the adult
human pancreas. Nat. Med. 12, 310—316.
Hara, M., Wang, X., Kawamura, T., Bindokas, V.P., Dizon, R.F.,
Alcoser, S.Y., Magnuson, M.A., Bell, G.I., 2003. Transgenic mice
with green fluorescent protein-labeled pancreatic beta-cells.
Am. J. Physiol. Endocrinol. Metab. 284, E177—183.
Hess, D., Li, L., Martin, M., Sakano, S., Hill, D., Strutt, B., Thyssen,
S., Gray, D.A., Bhatia, M., 2003. Bone marrow-derived stem cells
initiate pancreatic regeneration. Nat. Biotechnol. 21, 763—770.
Jiang, W., Shi, Y., Zhao, D., Chen, S., Yong, J., Zhang, J., Qing, T.,
Sun, X., Zhang, P., Ding, M., et al., 2007. In vitro derivation of
functional insulin-producing cells from human embryonic stem
cells. Cell Res. 17, 333—344.
Kohler, G., Milstein, C., 1975. Continuous cultures of fused cells
secreting antibody of predefined specificity. Nature 256, 495—497.
194 C. Dorrell et al.Kumar, U., Sasi, R., Suresh, S., Patel, A., Thangaraju, M., Metrakos,
P., Patel, S.C., Patel, Y.C., 1999. Subtype-selective expression of
the five somatostatin receptors (hSSTR1-5) in human pancreatic
islet cells: a quantitative double-label immunohistochemical
analysis. Diabetes 48, 77—85.
Latif, Z.A., Noel, J., Alejandro, R., 1988. A simple method of
staining fresh and cultured islets. Transplantation 45, 827—830.
Lukowiak, B., Vandewalle, B., Riachy, R., Kerr-Conte, J., Gmyr, V.,
Belaich, S., Lefebvre, J., Pattou, F., 2001. Identification and
purification of functional human beta-cells by a new specific
zinc-fluorescent probe. J. Histochem. Cytochem. 49, 519—528.
Maffei, A., Liu, Z., Witkowski, P., Moschella, F., Del Pozzo, G., Liu,
E., Herold, K., Winchester, R.J., Hardy, M.A., Harris, P.E., 2004.
Identification of tissue-restricted transcripts in human islets.
Endocrinology 145, 4513—4521.
Marzorati, S., Pileggi, A., Ricordi, C., 2007. Allogeneic islet
transplantation. Expert Opin. Biol. Ther. 7, 1627—1645.
Mason, D., Andre, P., Bensussan, A., Buckley, C., Civin, C., Clark, E.,
de Haas, M., Goyert, S., Hadam, M., Hart, D., et al., 2002. CD
antigens 2002. Blood 99, 3877—3880.
Morton, R.A., Geras-Raaka, E., Wilson, L.M., Raaka, B.M., Gershen-
gorn, M.C., 2007. Endocrine precursor cells from mouse islets are
not generated by epithelial-to-mesenchymal transition of
mature beta cells. Mol. Cell. Endocrinol. 270, 87—93.
Narushima, M., Kobayashi, N., Okitsu, T., Tanaka, Y., Li, S.A., Chen,
Y., Miki, A., Tanaka, K., Nakaji, S., Takei, K., et al., 2005. A
human beta-cell line for transplantation therapy to control type
1 diabetes. Nat. Biotechnol. 23, 1274—1282.Ouziel-Yahalom, L., Zalzman, M., Anker-Kitai, L., Knoller, S., Bar, Y.,
Glandt, M., Herold, K., Efrat, S., 2006. Expansion and rediffer-
entiation of adult human pancreatic islet cells. Biochem.
Biophys. Res. Commun. 341, 291—298.
Portela-Gomes, G.M., Hacker, G.W., Weitgasser, R., 2004. Neuroen-
docrine cell markers for pancreatic islets and tumors. Appl.
Immunohistochem. Mol. Morphol. 12, 183—192.
Seeberger, K.L., Dufour, J.M., Shapiro, A.M., Lakey, J.R., Rajotte, R.V.,
Korbutt, G.S., 2006. Expansion of mesenchymal stem cells from
human pancreatic ductal epithelium. Lab. Invest. 86, 141—153.
Street, C.N., Lakey, J.R., Shapiro, A.M., Imes, S., Rajotte, R.V., Ryan,
E.A., Lyon, J.G., Kin, T., Avila, J., Tsujimura, T., Korbutt, G.S.,
2004. Islet graft assessment in the Edmonton Protocol: implications
for predicting long-termclinical outcome. Diabetes 53, 3107—3114.
Todorov, I., Omori, K., Pascual, M., Rawson, J., Nair, I., Valiente, L.,
Vuong, T., Matsuda, T., Orr, C., Ferreri, K., et al., 2006. Gener-
ation of human islets through expansion and differentiation of
non-islet pancreatic cells discarded (pancreatic discard) after
islet isolation. Pancreas 32, 130—138.
Weinberg, N., Ouziel-Yahalom, L., Knoller, S., Efrat, S., Dor, Y., 2007.
Lineage tracing evidence for in vitro dedifferentiation but rare pro-
liferation of mouse pancreatic beta-cells. Diabetes 56, 1299—1304.
Williams, C.V., Stechmann, C.L., McLoon, S.C., 1992. Subtractive
immunization techniques for the production of monoclonal
antibodies to rare antigens. Biotechniques 12, 842—847.
Yatoh, S., Dodge, R., Akashi, T., Omer, A., Sharma, A., Weir, G.C.,
Bonner-Weir, S., 2007. Differentiation of affinity-purified human
pancreatic duct cells to beta-cells. Diabetes 56, 1802—1809.
